If you wish to hear about our latest blogs, podcasts, webinars, and team news, simply enter your email to sign up to our monthly newsletter.
HRW is committed to measuring, managing and reducing their GHG emissions with the overall aim of limiting climate change. This document sets out the methodology that HRW used to calculate their carbon emissions for FY23/24.
GHG emissions have been measured for all operations relating to Healthcare Research Worldwide Ltd, “HRW” including any subsidiaries or joint ventures.
Emissions for FY23/24 cover those from 1st April 2023 – 31st March 2024 inclusive.
GHG emissions for the company have been measured in accordance with the GHG Protocol Corporate Standard, with reporting boundaries defined by the operational consolidation (control) approach.
Scope 2 emissions have been measured using both the location-based and market-based method, with the latter being used for performance tracking (baselines and targets).
GHG emissions have been calculated using conversion factors for carbon dioxide (CO2), methane (CH4) and nitrous oxide (N2O). There are no known emissions of other greenhouse gases. Emissions factors used were the UK Government conversion factors for 2024 and CEDA by Watershed.
Emissions reported cover all relevant scope 1, 2 and 3 sources. A description of all emission sources and their calculation method is presented in Table 1.
Table: Emission sources and methodology
HRW’s total measured scope 1, 2 and 3 emissions for FY23/24 were 2,653 tCO2e (market-based method).
Table 2: HRW’s scope 1, 2 and 3 GHG emissions for FY23/24.
Should reported GHG emissions change significantly due to merger, acquisition, change of calculation methodology or discovery of significant errors, the baseline will be retrospectively recalculated and externally published. The significance threshold for this is set as a cumulative impact (increase or decrease) of >=5%.